484 reports of this reaction
1.6% of all DORNASE ALFA reports
#12 most reported adverse reaction
PULMONARY FUNCTION TEST DECREASED is the #12 most commonly reported adverse reaction for DORNASE ALFA, manufactured by Genentech, Inc.. There are 484 FDA adverse event reports linking DORNASE ALFA to PULMONARY FUNCTION TEST DECREASED. This represents approximately 1.6% of all 29,815 adverse event reports for this drug.
Patients taking DORNASE ALFA who experience pulmonary function test decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY FUNCTION TEST DECREASED is a less commonly reported adverse event for DORNASE ALFA, but still significant enough to appear in the safety profile.
In addition to pulmonary function test decreased, the following adverse reactions have been reported for DORNASE ALFA:
The following drugs have also been linked to pulmonary function test decreased in FDA adverse event reports:
PULMONARY FUNCTION TEST DECREASED has been reported as an adverse event in 484 FDA reports for DORNASE ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY FUNCTION TEST DECREASED accounts for approximately 1.6% of all adverse event reports for DORNASE ALFA, making it a notable side effect.
If you experience pulmonary function test decreased while taking DORNASE ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.